Similar articles

• Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.

  Kremer AB, Barnes L, Hirsch RL, Goldstein G. Kremer AB, et al. Transplant Proc. 1987 Apr;19(2 Suppl 1):54-7. Transplant Proc. 1987. PMID: 3105141 Clinical Trial. No abstract available.
• Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy.

  Hirsch RL, Layton PC, Barnes LA, Kremer AB, Goldstein G. Hirsch RL, et al. Transplant Proc. 1987 Apr;19(2 Suppl 1):32-6. Transplant Proc. 1987. PMID: 3105138 No abstract available.
• A U.S. clinical study of Orthoclone OKT3 in renal transplantation.

  Norman DJ, Shield CF 3rd, Barry J, Henell K, Funnell MB, Lemon J. Norman DJ, et al. Transplant Proc. 1987 Apr;19(2 Suppl 1):21-7. Transplant Proc. 1987. PMID: 3105136 Clinical Trial. No abstract available.
• Clinical development of Orthoclone OKT3.

  Cosimi AB. Cosimi AB. Transplant Proc. 1987 Apr;19(2 Suppl 1):7-16. Transplant Proc. 1987. PMID: 3105142 Review. No abstract available.
• Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.

  McLigeyo SO, Notghi A, Anderton JL, Dick J. McLigeyo SO, et al. East Afr Med J. 1990 Sep;67(9):667-73. East Afr Med J. 1990. PMID: 2123786 Review.